Clinilabs Drug Development Corporation
Eatontown, New Jersey, 07724, United States
NCT Number: NCT05028764
To examine range of tissue frataxin (FXN) concentrations, specific ribonucleic acids, other proteins and specialized lipids in the buccal cells, blood, and skin cells of normal healthy volunteers without Friedreich's ataxia (FRDA).
Looking for future studies?
Notify Me18 year–50 year
All sexes
Observational
Eatontown, New Jersey, 07724, United States
Primary Objective: To examine the range of tissue frataxin (FXN) concentrations in the buccal cells, blood, and skin cells of normal healthy volunteers without FRDA.
Secondary Objective: To examine the range of specific ribonucleic acids (RNAs), other proteins, and specialized lipids in the buccal cells, blood, and skin cells of normal healthy volunteers without FRDA.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers
Time frame: 1 day
Range of tissue frataxin levels in buccal cells, blood and skin cells
Time frame: 1 day
Range of specific ribonucleic acids (RNAs), other proteins, and specialized lipids in buccal cells and blood
Larimar Therapeutics, Inc.
Industry
A Study to Determine the Range of Tissue Frataxin Concentrations and Other Potential Biomarkers for Friedreich's Ataxia in Normal Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04346238
Brain Diseases, Central Nervous System Diseases
Montpellier, France
View Trial DetailsNCT04921930
Brain Diseases, Central Nervous System Diseases
Paris, France
View Trial DetailsNCT04577352
Brain Diseases, Central Nervous System Diseases
Los Angeles, California, United States
View Trial DetailsNCT02255435
Brain Diseases, Central Nervous System Diseases
Los Angeles, California, United States
View Trial Details